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Less than 5 years after the atomic bombings
of Hiroshima and Nagasaki, it was established
that there was an excess of leukemia among
the atomic bomb survivors (Committee for
the Compilation of Materials 1981). Japanese
physicians noted the unusual number 
of leukemia cases among survivors, and
researchers associated with the Atomic Bomb
Casualty Commission (ABCC) subsequently
confirmed the observation in a series of epi-
demiologic surveys (Folley et al. 1952;
Valentine 1951). When examined by leukemia
subtype, researchers with the ABCC reported
substantial excesses of acute forms of leukemia
and chronic myeloid leukemia among A-bomb
survivors. In contrast, no excess of chronic
lymphocytic leukemia (CLL) was observed
(Finch et al. 1969; Ishimaru et al. 1969).
A few years later, Court-Brown and Doll
(1957) reported the results of a study of mor-
tality among adult British males who had
received X-ray therapy for an arthritic condi-
tion (ankylosing spondylitis). When examin-
ing leukemia by subtype, it was noted that in
the ﬁrst 5 years postirradiation, deaths due to
acute forms of leukemia and chronic myeloid
leukemia were in substantial excess among
these patients. The researchers found no
excess of CLL (Court-Brown and Doll 1965;
Darby et al. 1987). These ﬁndings, and their
consistency with those of the A-bomb sur-
vivor studies, led investigators to postulate
that there were differences in the radio-
genicity of leukemia by subtype, with CLL
being much less readily inducible by exposure
to ionizing radiation than other types of
leukemia (Darby et al. 1987).
Over time, this hypothesis has come to be
expressed more strongly (Department of
Health and Human Services 2002). Although
most lymphatic and hematopoietic tissues are
considered to be extremely sensitive to the
carcinogenic effects of ionizing radiation, it is
routinely presumed that CLL incidence is
entirely insensitive to the carcinogenic effects
of radiation. This assertion has become insti-
tutionalized in the U.S. Energy Employees
Occupational Illness Compensation Program,
under which all claims for CLL must be
rejected because of the presumption that the
risk of radiation-induced CLL is zero
(Department of Health and Human Services
2002). In this article, we review the basis for
the current presumption that CLL incidence
is entirely unaffected by ionizing radiation
exposure.
Methods
In this article we present a review of the
molecular, clinical, and epidemiologic evi-
dence regarding the radiogenicity of CLL. We
begin with a review of the current understand-
ing of the molecular basis of CLL. Next, we
review the clinical attributes of CLL and dis-
cuss the implications for etiologic research.
Finally, we consider the epidemiologic litera-
ture on associations between external exposure
to ionizing radiation and CLL risk. We focus
on studies that have played a prominent role
in the literature on the induction of leukemia,
and specifically CLL, by ionizing radiation
[National Research Council, Committee on
the Biological Effects of Ionizing Radiation
(BEIR V) 1990; United Nations Scientific
Committee on the Effects of Atomic Radiation
2000]. Studies of the effects of exposure to
ionizing radiation in utero or in childhood
(e.g., for thymic enlargement or tinea capitis)
were not included in this review because the
average age of study participants at the end of
follow-up tended to be less than the age at
which CLL typically occurs.
The Revised European American
Lymphoma classiﬁcation scheme (Harris et al.
1994), which is widely accepted and was
adopted by the World Health Organization,
considers B-cell CLL and small lymphocytic
lymphoma [SLL, a subtype of non-Hodgkin’s
lymphoma (NHL)] to be a single disease entity,
in recognition of the biologic and clinical
similarities between these B-lymphocyte malig-
nancies (Harris et al. 1999). Epidemiologic evi-
dence of associations between ionizing
radiation and risk of SLL would therefore be of
interest in the context of this evaluation.
However, epidemiologic studies have only
recently begun to evaluate risk factors for SLL,
and studies available for this review did not
report results speciﬁcally for SLL.
Many of the epidemiologic studies that we
reviewed reported results of analyses of stan-
dardized mortality ratios (SMRs) or standard-
ized incidence ratios (SIRs). We have included
95% conﬁdence intervals (CIs) for these ﬁnd-
ings. If a 95% CI was not reported in the text,
we have calculated approximate 95% CIs
(Rothman and Boice 1979). In this article we
generically refer to measures of association
based on odds ratios and rate ratios as esti-
mates of relative risk (RR). Many of the stud-
ies that we reviewed reported estimates of
radiation dose to the bone marrow. We have
included these values in the text in order to
allow comparison of the magnitude of doses
between study populations. We report radia-
tion dose estimates in millisieverts. Some of
the reviewed papers reported dose estimates in
milligrays, a physical quantity describing
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The U.S. government recently implemented rules for awarding compensation to individuals with
cancer who were exposed to ionizing radiation while working in the nuclear weapons complex.
Under these rules, chronic lymphocytic leukemia (CLL) is considered to be a nonradiogenic form
of cancer. In other words, workers who develop CLL automatically have their compensation claim
rejected because the compensation rules hold that the risk of radiation-induced CLL is zero. In
this article we review molecular, clinical, and epidemiologic evidence regarding the radiogenicity
of CLL. We note that current understanding of radiation-induced tumorigenesis and the etiology
of lymphatic neoplasia provides a strong mechanistic basis for expecting that ionizing radiation
exposure increases CLL risk. The clinical characteristics of CLL, including prolonged latency and
morbidity periods and a low case fatality rate, make it relatively difﬁcult to evaluate associations
between ionizing radiation and CLL risk via epidemiologic methods. The epidemiologic evidence
of association between external exposure to ionizing radiation and CLL is weak. However, epi-
demiologic ﬁndings are consistent with a hypothesis of elevated CLL mortality risk after a latency
and morbidity period that spans several decades. Our ﬁndings in this review suggest that there is
not a persuasive basis for the conclusion that CLL is a nonradiogenic form of cancer. Key words:
chronic lymphocytic leukemia, compensation, ionizing radiation, radiogenicity. Environ Health
Perspect 113:1–5 (2005). doi:10.1289/ehp.7433 available via http://dx.doi.org/ [Online
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Research Reviewenergy deposited per unit mass. For X-rays
and gamma-rays, we assume a quality factor of
unity; hence, 1 mGy = 1 mSv.
Results
Molecular basis of CLL. CLL is a monoclonal
disease of lymphocytes. Like other lymphoid
cancers, CLL pathogenesis appears to be driven
both by functional aberrations in immune
function (Stevenson et al. 1998) and by
somatic mutations, some of which may be a
consequence of environmental exposures
(Magrath 1992). Using contemporary molecu-
lar cytogenetic methods, chromosomal abnor-
malities are detected in most (> 80%) CLL
cases (Stilgenbauer et al. 2002). Two tumor
suppressor genes that are inactivated as a result
of common CLL mutations, p53 and ATM,
are established causal contributors to malignant
transformation. Therefore, these and other
common somatic mutations are believed to
play a causal role in the etiology of CLL.
The type of mutations observed in clonal
cells obtained from CLL patients, primarily
deletions of chromosomal material, require
double-strand breaks of the chromosomal
DNA in order to occur (Dewald et al. 2003;
Stilgenbauer et al. 2000). Double-strand
breaks (in one-half of the gene pair) are rou-
tinely generated during immunoglobulin gene
rearrangement during normal lymphocyte
maturation. However, in marked contrast with
other lymphocytic malignancies, somatic
mutations (speciﬁcally, translocations) involv-
ing immunoglobulin genes are rare in CLL
(Stilgenbauer et al. 2002). This suggests that
environmental exposures, rather than endoge-
nous processes related to gene rearrangement
during normal lymphocyte maturation, play an
important role in producing the somatic muta-
tions that contribute to the genesis of CLL.
It is well established that ionizing radia-
tion has the ability to produce double-strand
breaks in chromosomal DNA (United
Nations Scientiﬁc Committee on the Effects
of Atomic Radiation 2000). The primary
mechanism by which biologic damage occurs
is believed to be via the creation of ionized
atoms and molecules that become chemically
reactive. This can occur directly via ionization
of a critical molecule, such as DNA, or indi-
rectly via ionization of nearby molecules, such
as water.
Like all cancers, CLL requires multiple
mutations before neoplastic transformation
occurs. Rather than arising due to a loss of
cellular control and rapid proliferation of
clonal lymphocytes, in the case of CLL the
carcinogenic process is believed to typically
involve an early event that causes a failure of
apoptosis. The effectively immortalized lym-
phocyte may then persist in the body for
years, increasing the likelihood that the cell
will acquire additional mutations leading to
full neoplastic transformation and the accu-
mulation of clonal cells that may result in
clinical symptoms of malignant disease
(Voutsadakis 2000). This multistage process
of neoplastic transformation is believed to
account for many of the observed characteris-
tics of the natural history of the disease and,
specifically, the protracted induction and/or
latency period associated with CLL.
Ionizing radiation exposure could play a
role in one or more stages of this multistage
process of neoplastic transformation. In addi-
tion, it is plausible that some early-stage muta-
tional events may increase the likelihood of
ionizing radiation exposure inﬂuencing later-
stage transformations. For example, in a con-
siderable proportion of CLL clones (~ 20%),
the ATM gene is mutated; the ATM gene
product is known to be involved in the repair
of DNA double-strand breaks (Dunst et al.
1998; Humphreys et al. 1989; Jones et al.
1995; Parshad et al. 1985; Stilgenbauer et al.
2000), and mutations of this gene are associ-
ated with increased vulnerability to the car-
cinogenic effects of ionizing radiation. The
inactivation of this tumor suppressor gene is
not necessarily due to radiation exposure itself,
but could occur as an early event that increases
susceptibility to subsequent ionizing-radiation–
induced mutations that result in progression of
the carcinogenic process to CLL.
Clinical aspects of CLL. Compared with
acute forms of leukemia and chronic myeloid
leukemia, CLL is neither fast progressing nor
highly fatal. With an increasing number of lym-
phocytes in the circulating bloodstream, even-
tually a person with CLL may present with
symptoms of clinical signiﬁcance such as short-
ness of breath, weight loss, or fever. However,
often a patient with CLL is diagnosed during
a routine medical examination that is not
conducted because of any overt symptoms of
disease (Rozman and Montserrat 1995).
The clinical aspects of the disease are
important considerations from an epidemio-
logic perspective because they render CLL
more prone to misclassification than acute
lymphocytic and myeloid forms of leukemia.
Even when patients present with overt symp-
toms of disease, diagnostic classification of
CLL has long been characterized by a lack of
consistency. Until recently, the same patient
might be diagnosed with CLL by one hema-
tologist and diagnosed with NHL by another,
depending upon the classiﬁcation scheme used
by the diagnosing physician (Harris et al.
2000a, 2000b). CLL is now considered analo-
gous to SLL (a subtype of NHL), the differ-
ence between the two being a function of the
extent to which the tumor involves the bone
marrow (CLL) versus solid tissue (SLL), with
the recognition that both solid and circulating
phases are present in many lymphoid neo-
plasms (Harris et al. 1999).
Particularly problematic are studies that
rely on the use of cause of death information
obtained from the death certiﬁcate as a proxy
for information on CLL incidence. Cause of
death information provides a relatively good
measure of disease incidence if the disease
progresses rapidly and has a high probability
of leading to death. These are not the charac-
teristics of CLL. Patients diagnosed with CLL
often live many years without developing evi-
dence of signiﬁcant symptoms, and as a con-
sequence of the typically old age at onset of
CLL, many patients die with the disease, but
from causes other than CLL (Crespo et al.
2003). In the United States, for example, the
5-year survival rate after a diagnosis of CLL is
> 70% (Ries et al. 2003). Therefore, CLL is
not necessarily the underlying cause of death
recorded on a death certificate and, in fact,
may not be indicated on the death certiﬁcate
at all. In addition, deaths attributed to CLL
tend to occur at very old ages when the valid-
ity of death certiﬁcate information tends to be
poorest (Ron et al. 1994b). Furthermore, the
direct repercussions or complications of CLL
are often nonspecific, including immuno-
deﬁciency, and may increase the likelihood of
infectious or malignant disease, thereby
increasing the opportunity for conditions
other than CLL to be recorded as the under-
lying cause of death. Secondary cancers fre-
quently follow CLL incidence, and there is
the possibility that the malignant clone of
CLL can increase in malignancy due to addi-
tional chromosome breaks (dedifferentiation)
and develop into a highly malignant B-cell
NHL. Again, with high probability, the sec-
ondary cancer would be documented as the
cause of death. This observation is supported
by evidence from a recent study of patients
with CLL in which Kyasa et al. (2004) found
that the second malignancy was the primary
cause of death recorded for 34% of CLL
patient deaths. 
Epidemiologic findings regarding radi-
ogenicity. Table 1 lists a number of epidemio-
logic studies of populations exposed to
ionizing radiation and describes the numbers
of cases and study findings for associations
with CLL by exposure type.
Atomic bomb. The Lifespan Study (LSS)
of the Japanese atomic bomb survivors has
served as one of the primary studies for evalua-
tion of the carcinogenic effects of ionizing radi-
ation. However, for evaluation of CLL risk
after exposure to ionizing radiation, the LSS
provides minimal information because the
incidence of CLL is extremely low in Asian
populations (Finch and Linet 1992; Groves
et al. 1995). Furthermore, much of the
research published over the past 50 years on
the effects of the atomic bomb on CLL inci-
dence and mortality in the LSS suffered prob-
lems of case misclassification (Preston et al.
Review | Richardson et al.
2 VOLUME 113 | NUMBER 1 | January 2005 • Environmental Health Perspectives1994). After an extensive review of hemato-
logic specimens for leukemia cases identiﬁed
during the period from 1945 through 1980, it
was determined that 7 of the 10 CLL cases reg-
istered during that period were, in fact, not
CLL. These were determined to be cases of
acute T-cell leukemia (ATL), a relatively com-
mon disease among Nagasaki residents regard-
less of their status as an A-bomb survivor. ATL
is strongly related to infection by the human
T-lymphotropic virus type 1, which is par-
ticularly prevalent in the Nagasaki region.
Consequently, reports on radiation–CLL asso-
ciations that are based on information collected
before this reclassiﬁcation of leukemia are of
questionable reliability because of these prob-
lems of case misclassiﬁcation. With the reclassi-
fication of leukemia cases, analyses of cancer
incidence among 86,293 survivors (average
bone marrow dose estimated as 300 mSv) over
the period 1950–1987 include only four CLL
cases. Given the small number of CLL cases,
speciﬁc analyses of radiation–CLL associations
have not been reported (Preston et al. 1994;
Tomonaga et al. 1991).
Radiation therapy for nonmalignant dis-
ease. Studies of patients treated by radiotherapy
provide more informative results because they
include larger numbers of CLL cases. Of partic-
ular importance, given the size of the study
cohort, duration of follow-up, and average
magnitude of radiation dose, are the results of a
study of cancer mortality among approximately
14,000 British ankylosing spondylitis patients
who were treated by X irradiation between
1935 and 1954 (average bone marrow dose
estimated as 4,400 mSv). With vital status fol-
low-up through 1991, it was found that these
patients were more likely to have a death attrib-
uted to CLL than were members of the general
population (observed = 7; SMR = 1.44; 95%
CI, 0.6–2.8) (Weiss et al. 1995). Furthermore,
consistent with expectations of long latency and
morbidity periods for CLL mortality, excess
CLL mortality was observed almost exclusively
in the period ≥ 25 years after irradiation (in
contrast to acute and myeloid leukemia, for
which a peak in excess mortality was observed
in the first 5 years posttreatment). Under a
25-year exposure lag assumption, a 2-fold
excess of CLL mortality was observed
(observed = 6; SMR = 1.97; 95% CI, 0.7–4.3)
(Weiss et al. 1994).
Damber et al. (1995) examined the inci-
dence of CLL in a cohort of 20,204 Swedish
patients who were treated by radiotherapy
between 1950 and 1964 for benign diseases of
the locomotor system such as ankylosing
spondylitis, arthrosis, and spondylosis (aver-
age bone marrow dose estimated as 400 mSv).
Compared with the British ankylosing
spondylitis patients, the radiation doses deliv-
ered to these patients were typically an order
of magnitude lower, and only small parts of
the body were irradiated (Damber et al.
1995). Patients were classified into three
groups based on estimated radiation doses
(< 0.20, 0.20–0.50, and > 0.50 Gy), and SIRs
were calculated under a 0-year exposure lag
assumption (there was no evaluation of varia-
tion in cancer risk with time since irradia-
tion). There was a slight deficit of CLL
among patients who received the lowest radia-
tion doses (observed = 1; SIR = 0.94; 95%
CI, 0.6–1.5) and a small excess of CLL
among patients in the upper two dose groups
(0.20–0.50 Gy: observed = 15; SIR = 1.17;
95% CI, 0.7–1.9; > 0.50 Gy: observed = 16;
SIR = 1.18; 95% CI, 0.7–1.9). 
Among 12,955 female patients who were
treated by radiotherapy for benign gynecologic
disorders (median dose to active bone marrow
estimated as 1,200 mSv), CLL mortality rates
(pooled together with lymphatic leukemia not
otherwise speciﬁed) were elevated when com-
pared with general population mortality rates
(observed = 17; SMR = 1.8; 95% CI, 1.0–2.9)
(Inskip et al. 1993). Consistent with expecta-
tions of a protracted latency and morbidity
period, there was no excess of CLL mortality in
the ﬁrst 10 years of follow-up (observed = 1;
SMR = 0.93; 95% CI, 0.0–5.2). In subsequent
decades after irradiation, however, there was an
excess of CLL mortality among irradiated
patients. Under 20- and 30-year exposure lag
assumptions, the ratios of observed to expected
CLL deaths were 1.64 (observed = 10; 95%
CI, 0.8–3.0) and 2.2 (observed = 7; 95% CI,
0.9–4.5), respectively. A comparison was also
drawn using an internal referent population (a
group of 3,185 patients with treatments other
than radiotherapy). Comparisons between irra-
diated and nonirradiated patients by leukemia
subtype produced highly unstable results
because of the small number of leukemia cases
in the nonirradiated group. The overall rate
ratio for CLL comparing irradiated to nonirra-
diated patients was 1.1 (90% CI, 0.5–3.0);
under 20- and 30-year exposure lag assump-
tions, the rate ratios for CLL comparing irradi-
ated to nonirradiated patients were 1.3 and
2.3, respectively.
Investigations of CLL mortality among
women treated by radiotherapy for excessive
uterine bleeding (metropathia hemorrhagica)
(Darby et al. 1994) and women treated by
radiotherapy for infertility or amenorrhea
(Ron et al. 1994a) have not reported on the
risk of CLL after irradiation because of the
small numbers of CLL cases (one and two
CLL deaths, respectively) observed in these
cohorts.
Radiotherapy for malignant disease.
Studies of cancer after radiotherapy treatment
for a previous cancer offer the opportunity to
study populations that have received relatively
high doses of radiation. However, the radiation
doses delivered for cancer therapy tend to be
extremely high and localized; the intended
effect is killing cells in the irradiated area that
effectively prevents cancer induction. Although
cell killing is also an issue in radiotherapy for
benign diagnoses, in tumor irradiation it repre-
sents the original goal of the therapy, and
attenuation of the dose–response relation for
cancer induction may therefore be accentuated.
In addition, the effects of radiation exposure
on cancer incidence may differ for a healthy
population than for a group of patients who
are hospitalized for cancer treatment. Not only
are these patients being treated for an existing
cancer, but they also many receive chemother-
apy in conjunction with radiotherapy, which
may influence subsequent cancer incidence.
Further, CLL tends to be a chronic disease
with a prolonged latency period, and therefore
survivorship is important for a diagnosis of
CLL; if mortality rates for causes other than
CLL differ with respect to radiotherapy, then
bias may occur in estimates of radiation–CLL
associations.
In a cohort study of second cancers after
radiotherapy for invasive cancer of the uterine
cervix among 182,040 women (average bone
marrow dose was estimated as 7,100 mSv),
Boice et al. (1985) examined the observed and
expected (O/E) numbers of second cancers. In
the first decade after irradiation, there were
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Table 1. Epidemiologic studies of populations exposed to ionizing radiation and risk of CLL: numbers of
cases and summary of study ﬁndings by type of exposure.
CLL Radiation
Type of exposure/study Reference cases risk
Atomic bomb
Japanese survivors  Preston et al. 1994 4 NR
Radiotherapy
Ankylosing spondylitis  Weiss et al. 1994, 1995 7 +a
Benign disorders of the locomotor system  Damber et al. 1995 17 +b
Benign gynecologic disorders  Inskip et al. 1993 17 +a
Cervical cancer  Boice et al. 1985, 1987 52 –
Uterine cancer  Curtis et al. 1994 54 –
Breast cancer  Curtis et al. 1989 10 +
Occupation
Nuclear industry  Cardis et al. 1995 27 –
Abbreviations: –, no evidence of radiation risk; +, evidence for radiation risk; NR, results not reported. 
aFor the period ≥ 25 years after irradiation. bAmong those receiving ≥ 0.20 Gy. fewer than expected cases of CLL (observed = 9;
O/E = 0.7; 95% CI, 0.3–1.3), whereas under a
20-year exposure lag assumption a small excess
of CLL mortality was reported (observed = 3;
O/E = 1.25; 95% CI, 0.3–3.7). A case–control
study of secondary cancers after radiotherapy
for invasive cancer of the uterine cervix was
conducted building upon this cohort analysis
(Boice et al. 1987). The study included
leukemia cases that were diagnosed at least
1 year after diagnosis of cervical cancer, with
four controls matched to each case. CLL inci-
dence among patients treated by radiotherapy
was compared with CLL incidence among
patients treated by other means. No excess of
CLL was observed when comparing patients
treated by radiotherapy with other patients
(RR = 1.03; 90% CI, 0.3–3.9). As indicated
by the 90% CIs, the ﬁndings of the study are
highly imprecise, largely because almost all
cervical cancer cases were treated by radio-
therapy, the treatment of choice during the
study period. All results for analyses of CLL
pertain to a 1-year exposure lag assumption
with no evaluation of variation in risk with
time since irradiation.
In case–control studies of leukemia after
radiotherapy for invasive cancer of the uterine
corpus (Curtis et al. 1994) and breast cancer
(Curtis et al. 1989), leukemia cases were identi-
ﬁed between 1935 and 1985 using cancer reg-
istry data, and controls were matched by cancer
registry, age, year of diagnosis, and race. Among
patients treated for cancer of the uterine corpus,
the RR for CLL, comparing patients treated by
radiotherapy with others, was 0.90 (95% CI,
0.4–1.9). Among patients treated by radiother-
apy for breast cancer, the RR for CLL, compar-
ing patients treated by radiotherapy with others,
was 1.84 (95% CI, 0.5–6.7). Neither of these
studies reported on evaluation of variation in
the association between CLL and radiotherapy
treatment with time since treatment.
Other studies of populations externally
exposed to ionizing radiation. The epidemio-
logic literature on cancer mortality among
workers in the nuclear industry provides mini-
mal basis for evaluating the effects of external
exposure to ionizing radiation on CLL because
of low statistical power. In analyses that com-
bined mortality information on 95,673 nuclear
industry workers in the United States, United
Kingdom, and Canada (average cumulative
dose was 40 mSv), a negative association
between ionizing radiation exposure and CLL
mortality was observed (excess RR per
Sv = –0.95; 90% CI, –4.0 to 9.4). However, it
stretches the practical limits of epidemiology to
expect to directly estimate risk from occupa-
tional cohort data in which few cases are
observed in the higher (e.g., ≥ 100 mSv ) dose
range; of the 27 CLL cases observed in the
international collaborative study of nuclear
workers, only 1 case was observed among
workers who had ≥ 100 mSv cumulative dose
(Cardis et al. 1995). Furthermore, the reported
results pertain to analyses under a 2-year
exposure lag assumption. Under a reasonable
exposure lag assumption for a slow-progress-
ing disease like CLL (e.g., 20 years), the dis-
tribution of CLL cases with respect to
cumulative radiation dose would tend to shift
farther toward zero. Such considerations
underline the limited power of nuclear worker
cohort studies to derive radiation risk estimates
for CLL mortality.
Studies of patients exposed to ionizing
radiation via diagnostic X-ray procedures also
provide minimal information about the asso-
ciation between ionizing radiation exposure
and CLL incidence. For example, although
cancer mortality has been examined among
Massachusetts tuberculosis patients who were
examined by X-ray fluoroscopy, no case of
CLL was observed among these patients
(Davis et al. 1989).
Discussion
As ionizing radiation is transmitted through
the human body, energy is transferred to the
surrounding tissue and can produce biologic
damage, including double-strand breaks in
chromosomal DNA (United Nations Scientiﬁc
Committee on the Effects of Atomic Radiation
2000). CLL appears to be similar to other
hematologic malignancies whose pathogenesis
involves structural changes on the chromoso-
mal level that cause mutational changes on the
molecular level, altering important cellular
functions, and, ultimately, leading to malig-
nant transformation of a cell (Irons and
Stillman 1996). Therefore, at the level of DNA
damage, there is no basis for the assumption
that the association between ionizing radiation
exposure and CLL risk would be zero. Rather,
there is strong evidence that the somatic muta-
tions that contribute to the genesis of CLL (in
a process that is likely to also involve aberra-
tions in immune function) can be produced
by ionizing radiation exposure.
Given the radiobiologic plausibility of radi-
ation-induced CLL, one would expect that the
conclusion that CLL is nonradiogenic would
be supported by a strong, consistent body of
epidemiologic evidence indicating that CLL is
an exception to the general principles of radia-
tion carcinogenesis. This is not the case.
Rather, there is limited epidemiologic evidence
with which to evaluate the relative radiogenic-
ity of CLL. Most studies include small num-
bers of cases, and few have conducted analyses
to adequately account for the prolonged
latency and morbidity periods of CLL.
A simple and parsimonious alternative to
the hypothesis that CLL is entirely insensitive
to ionizing radiation effects is that radiation does
inﬂuence CLL incidence, but this association 
is more difﬁcult to identify via epidemiologic
methods than the association between ionizing
radiation and acute lymphocytic and myeloid
forms of leukemia. Acute lymphocytic and
myeloid forms of leukemia arise as a conse-
quence of an increased rate of mitosis (due to
loss of cellular control over proliferation of
transformed cells). Consequently, the number
of white blood cells in the bone marrow and/or
circulating in the bloodstream of a patient with
acute lymphocytic or myeloid leukemia may
increase dramatically over a relatively short
period of time. In contrast, the fundamental
mechanism of accumulation of CLL-clonal
cells is an extension of the life span of the
transformed lymphocytes due to a failure of
apoptosis (Voutsadakis 2000), which leads to a
gradual accumulation of circulating CLL cells.
Thus, although clinical symptoms such as
shortness of breath, weight loss, or fever may
slowly develop over time, CLL is often diag-
nosed during routine physical examination of
asymptomatic elderly patients.
This long asymptomatic period (followed
by a protracted period of morbidity) has impor-
tant implications for epidemiologic investiga-
tions of radiation–CLL associations. It means
that case ascertainment may be poor and partly
obscured by competing causes of death.
Analytically, in order for an investigation of
radiation-induced CLL mortality to detect an
effect, the study must encompass a period of
follow-up that is long enough to allow for an
extended induction, latency, and morbidity
period after exposure occurs. Studies with short
duration of follow-up (e.g., one or two decades)
could observe no effect of ionizing radiation on
CLL simply because the time from exposure to
end of follow-up is less than the minimal
induction, latency, and morbidity period for
radiation-induced CLL mortality. Furthermore,
the ability to detect an association, if one exists,
requires relating CLL incidence or mortality to
exposures in the distant past using appropriate
methods of survival analysis. If the effect of
radiation on CLL risk only becomes apparent
many years (or a few decades) after irradiation,
then analyses conducted under relatively short
exposure lag assumptions may suffer serious
exposure misclassiﬁcation problems.
The Revised European American
Lymphoma classiﬁcation scheme (Harris et al.
1994) reﬂects a recent attempt to use immuno-
phenotypic and genetic characteristics in order
to classify lymphomas into subgroups that share
common clinical and pathologic characteristics.
To the extent that reﬁnements in disease classi-
ﬁcation improve the ability to identify cancer
cases that are similar in terms of etiology and
natural history (e.g., durations of latency and
morbidity periods), these efforts should
strengthen epidemiologic investigations.
However, constructing nosologic schemes pri-
marily with reference to considerations about
disease management and prognosis rather than
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ingly reﬁned categories, poses potential prob-
lems for epidemiologic research. Evidence of
the hazardous effects of an exposure may be
obscured by classiﬁcation of exposure-induced
cases into different groups based upon clinical
characteristics that are not etiologically relevant.
Further, as the classiﬁcation of diseases becomes
reﬁned, it becomes increasingly difﬁcult to con-
duct statistical analyses with adequate power to
address questions about the effects of an expo-
sure on disease incidence. Given the ability to
construct ever more reﬁned disease categoriza-
tions, it may be increasingly important to iden-
tify mechanistic and etiologic grounds for
aggregation of subtypes of diseases for epidemi-
ologic research purposes.
Conclusion
The assumption, under existing federal regu-
lations, that the risk of CLL after exposure to
ionizing radiation is zero is unlikely to be cor-
rect. In order to be correct, CLL must be an
exception to general principles of radiation
carcinogenesis. In this review we found no
support for that conclusion. Current under-
standing of the pathogenesis of CLL describes
a process in which there is an important role
played by mutational events that can be pro-
duced by exposure to ionizing radiation. The
epidemiologic evidence of radiation–CLL
associations is weak; however, given the limi-
tations of the reviewed studies, these ﬁndings
do not offer a persuasive basis for concluding
that CLL is an exception to general principles
of radiation carcinogenesis. In addition, there
is a problem of logical inconsistency if the
government continues to assert that CLL is
nonradiogenic whereas SLL is radiogenic.
Contemporary classification schemes hold
that B-cell CLL and SLL are analogous dis-
eases and should be considered as a single dis-
ease entity. It is possible that the magnitude
of the association between ionizing radiation
and CLL is smaller than that for other lym-
phomas and leukemias; evaluation of the
magnitude of this association is difﬁcult given
the limitations of existing epidemiologic data.
Nonetheless, it is likely that CLL incidence,
like other forms of cancer, will be increased
by exposure to ionizing radiation.
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